While the U.S. gave Huawei a 90-day reprieve, allowing American businesses to keep selling specific products to the Chinese firm, it also added more affiliates of the...Technologyread more
The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
While Hong Kong leader Carrie Lam painted a bleak picture of the city's economy, she expressed hope that dialogue with protesters could provide "a way out."China Politicsread more
China's pursuit of the Middle East may spur growth in the Islamic finance sector.World Economyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
U.S. President Donald Trump and his former White House communications director Anthony Scaramucci have had a public falling out recently.Politicsread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
Beijing will lower borrowing costs for companies, but that may not boost the economy as much as some hope.China Economyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Stocks in Asia were mixed on Tuesday, as the People's Bank of China published its new loan prime rates which would result in cheaper borrowing costs for companies.Asia Marketsread more
* Now sees EPS growth of 5%, vs earlier 3-5% target
* Surge in sales of Dupixent (Adds context)
PARIS, July 29 (Reuters) - Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.
The French drugmaker said on Monday it was now eyeing earnings per share growth of around 5% compared to an earlier target range of 3-5%.
The group is betting on the strong uptake of its drug Dupixent, initially prescribed for atopic dermatitis and later approved for asthma and chronic rhinosinusitis, as it continues marketing and launches of the product.
Sales of Dupixent, developed with U.S firm Regeneron rose 168% in the second quarter to 496 million euros ($551.80 million).
Second quarter business net income rose 4.9% at constant exchange rates to 1.64 billion euros while sales were up 3.9% to 8.63 billion euros.
Sanofi booked an 1.8 billion euros impairment charge of intangible assets in the quarter related to hemophilia product Eloctate, after lower sales in the U.S. and a revision of sales projections.
Eloctate's revenue fell 11%, a result of direct competition from Roche's Hemlibra, a newcomer in the market.
Eloctate was developed by U.S. hemophilia specialist Bioverativ which Sanofi agreed to buy last year for $11.6 billion.
($1 = 0.8988 euros) (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)